What Is The Current and Historic Market Size Analysis Of The Angiotensin Receptor Blockers (ARBs) Market?
The angiotensin receptor blockers (arbs) market has seen considerable growth due to a variety of factors.
• In recent times, the angiotensin receptor blockers (ARBs) market has experienced consistent growth. The market is set to expand from $8.51 billion in 2024 to $8.87 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.1%. The drivers of growth during the historic period include factors such as the hypertension epidemic, effective clinical results, the burden of cardiovascular diseases, renal protection, established clinical guidelines, the prescription of ARBs as the primary approach to treatment, and their cost-effectiveness.
What Is The Forecast For The Angiotensin Receptor Blockers (ARBs) Market?
The Angiotensin Receptor Blockers (ARBs) market is expected to maintain its strong growth trajectory in upcoming years.
• The market for angiotensin receptor blockers (ARBs) is projected to exhibit consistent expansion in the upcoming years, reaching $10.76 billion by 2029 with a compound annual growth rate (CAGR) of 5.0%.
This progression during the forecast period can be linked to various factors like precision medicine methodologies, increased attention on combination therapies, the worldwide market extension, approaches based on biomarker treatments, governmental initiatives, and heightened hypertension awareness. Key trends expected to shape the forecast period are the uptake of telemedicine, investment in research and improvement, competition from generics and patent expirations, digital health aids for medication compliance, and rivalry from biosimilars.
What Are The Essential Drivers Behind The Growth Of The Angiotensin Receptor Blockers ARBs Market?
The upward trend of cardiovascular diseases is predicted to fuel advancements in the angiotensin receptor blockers market. Often related to the accumulation of fatty components within the arteries (atherosclerosis) and heightened probability of blood clots, cardiovascular disease (CVD) influences the heart or blood vessels. The function of angiotensin receptor blockers is to alleviate blood pressure and enhance the heart's blood pumping ability by aiding in the relaxation of veins and arteries, thereby potentially reducing the threat of cardiovascular disease. For instance, the American College of Cardiology, a professional medical organization based in the US, revealed in August 2022 that the projected rates of heart-related risks and diseases are set to significantly rise in the United States by 2060. Consequently, the surging occurrence of cardiovascular diseases is encouraging the expansion of the angiotensin receptor blockers market.
How Is The Global Angiotensin Receptor Blockers ARBs Market Divided Into Key Segments?
The angiotensin receptor blockers (ARBs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Valsartan: Tablets, Capsules, Injectable Forms
2) By Telmisartan: Tablets, Capsules
3) By Losartan: Tablets, Oral Solution
4) By Irbesartan: Tablets, Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets, Oral Suspension
Pre-Book The Angiotensin Receptor Blockers ARBs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Angiotensin Receptor Blockers ARBs Market?
Companies at the forefront of the angiotensin receptor blocker market are making strides in product advancement, such as creating angiotensin receptor neprilysin inhibitors, to broaden treatment possibilities and increase positive patient results for those dealing with cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) constitute a category of drugs utilized in managing heart failure. For example, Glenmark Pharmaceuticals, a pharmaceutical corporation based in India, rolled out sacubitril + valsartan tablets in January 2023. These tablets are specifically designed to deal with heart failure, more specifically, heart failure with a reduced ejection fraction (HFrEF). The tools used in this therapy category are known as ARNI. Sacubitril boosts the natriuretic peptide (NP) scheme, which assists with fluid overload relief and encourages blood vessel expansion, whereas valsartan inhibits the renin-angiotensin system (RAS) to diminish blood pressure and lighten the heart's work burden. These two components, working in unison, augment heart failure symptom relief, mitigate the risk of cardiovascular death, and reduce the probability of heart failure-related hospitalizations. This treatment combination is commercially available under the brand name Sacu V.
Who Are the Key Players In The Angiotensin Receptor Blockers ARBs Market?
Major companies operating in the angiotensin receptor blockers (ARBs) market include:
• Pfizer Inc.
• Novartis AG
• Merck & Co. Inc.
• AstraZeneca Plc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Lupin Limited
• Dr. Reddy’s Laboratories Ltd.
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific
• Sanofi
• Johnson & Johnson
• Eli Lilly
• Bayer AG
• Abbvie Inc.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Zydus Cadila
• Glenmark Pharmaceuticals Ltd.
• Cipla Ltd.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC
• Zhejiang Huahai Pharmaceutical Co. Ltd.
• Boehringer Ingelheim Ltd.
• Astellas Pharma
What Are The Regional Insights Into The Angiotensin Receptor Blockers ARBs Market?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
